{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:30:20Z","timestamp":1793773820379,"version":"4.6.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T00:00:00Z","timestamp":1696550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T00:00:00Z","timestamp":1696550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100014481","name":"Kite Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014481","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s12325-023-02662-3","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T10:01:46Z","timestamp":1696586506000},"page":"5383-5398","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Matching-Adjusted Indirect Comparisons of Brexucabtagene Autoleucel with Alternative Standard Therapies for Relapsed\/Refractory B-Cell Acute Lymphoblastic Leukemia in Adult Patients"],"prefix":"10.1007","volume":"40","author":[{"given":"Bijal","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny M. H.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoling","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie E.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsveta","family":"Hadjiivassileva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio R.","family":"Kerbauy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally W.","family":"Wade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Keeping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,6]]},"reference":[{"key":"2662_CR1","unstructured":"National Cancer Institute. SEER cancer statistics review, 1975\u20132017. 2020. https:\/\/seer.cancer.gov\/csr\/1975_2017\/. Accessed 20 Apr 2023."},{"issue":"1","key":"2662_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0085554","volume":"9","author":"D Pulte","year":"2014","unstructured":"Pulte D, Jansen L, Gondos A, Katalinic A, Barnes B, Ressing M, et al. Survival of adults with acute lymphoblastic leukemia in Germany and the United States. PLoS ONE. 2014;9(1): e85554.","journal-title":"PLoS ONE"},{"issue":"suppl 5","key":"2662_CR3","doi-asserted-by":"publisher","first-page":"v69","DOI":"10.1093\/annonc\/mdw025","volume":"27","author":"D Hoelzer","year":"2016","unstructured":"Hoelzer D, Bassan R, Dombret H, Fielding A, Ribera JM, Buske C, et al. Acute lymphoblastic leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v69\u201382.","journal-title":"Ann Oncol"},{"issue":"3","key":"2662_CR4","first-page":"166","volume":"17","author":"S Paul","year":"2019","unstructured":"Paul S, Rausch CR, Nasnas PE, Kantarjian H, Jabbour EJ. Treatment of relapsed\/refractory acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2019;17(3):166\u201375.","journal-title":"Clin Adv Hematol Oncol"},{"issue":"24","key":"2662_CR5","doi-asserted-by":"publisher","first-page":"5568","DOI":"10.1002\/cncr.25354","volume":"116","author":"HM Kantarjian","year":"2010","unstructured":"Kantarjian HM, Thomas D, Ravandi F, Faderl S, Jabbour E, Garcia-Manero G, et al. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer. 2010;116(24):5568\u201374.","journal-title":"Cancer"},{"key":"2662_CR6","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines): acute lymphoblastic leukemia, Version 1.2023\u2014May 31, 2023. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/all.pdf. Accessed 27 June 2023."},{"key":"2662_CR7","unstructured":"ClinicalTrials.gov. Identifier NCT02614066, a study evaluating KTE-X19 in adult subjects with relapsed\/refractory B-precursor acute lymphoblastic leukemia (ZUMA-3). 2023. https:\/\/ClinicalTrials.gov\/show\/NCT02614066. Accessed 20 Apr 2023."},{"issue":"1","key":"2662_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood.2020009098","volume":"138","author":"BD Shah","year":"2021","unstructured":"Shah BD, Bishop MR, Oluwole OO, Logan AC, Baer MR, Donnellan WB, et al. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed\/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood. 2021;138(1):11\u201322.","journal-title":"Blood"},{"issue":"1","key":"2662_CR9","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s13045-022-01379-0","volume":"15","author":"BD Shah","year":"2022","unstructured":"Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, et al. Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study. J Hematol Oncol. 2022;15(1):170.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"2662_CR10","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1007\/s12325-019-00991-w","volume":"36","author":"I Proskorovsky","year":"2019","unstructured":"Proskorovsky I, Su Y, Fahrbach K, Vandendries E, Pag\u00e9 V, Onyekwere U, et al. Indirect treatment comparison of inotuzumab ozogamicin versus blinatumomab for relapsed or refractory acute lymphoblastic leukemia. Adv Ther. 2019;36(8):2147\u201360.","journal-title":"Adv Ther"},{"issue":"4","key":"2662_CR11","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1007\/s12325-019-0873-7","volume":"36","author":"J Song","year":"2019","unstructured":"Song J, Ma Q, Gao W, Cong Z, Xie J, Zimmerman Z, et al. Matching-adjusted indirect comparison of blinatumomab vs. inotuzumab ozogamicin for adults with relapsed\/refractory acute lymphoblastic leukemia. Adv Ther. 2019;36(4):950\u201361.","journal-title":"Adv Ther"},{"issue":"10299","key":"2662_CR12","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","volume":"398","author":"BD Shah","year":"2021","unstructured":"Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet (London, England). 2021;398(10299):491\u2013502.","journal-title":"Lancet (London, England)"},{"issue":"14","key":"2662_CR13","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1002\/cncr.32116","volume":"125","author":"HM Kantarjian","year":"2019","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, G\u00f6kbuget N, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019;125(14):2474\u201387.","journal-title":"Cancer"},{"issue":"9","key":"2662_CR14","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N, Fielding AK, Schuh AC, Ribera JM, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836\u201347.","journal-title":"N Engl J Med"},{"key":"2662_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"2662_CR16","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/0272989X17725740","volume":"38","author":"DM Phillippo","year":"2018","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Mak. 2018;38(2):200\u201311.","journal-title":"Med Decis Mak"},{"key":"2662_CR17","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submission to NICE. 2016."},{"issue":"9","key":"2662_CR18","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1200\/JCO.22.00642","volume":"41","author":"TW Laetsch","year":"2023","unstructured":"Laetsch TW, Maude SL, Rives S, Hiramatsu H, Bittencourt H, Bader P, et al. Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial. J Clin Oncol. 2023;41(9):1664\u20139.","journal-title":"J Clin Oncol"},{"key":"2662_CR19","unstructured":"ClinicalTrials.gov. Identifier NCT02228096, study of efficacy and safety of CTL019 in pediatric ALL patients (ENSIGN). 2020; https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02228096. Accessed 20 Apr 2023."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02662-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02662-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02662-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T11:10:08Z","timestamp":1698405008000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02662-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,6]]},"references-count":19,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["2662"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02662-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,6]]},"assertion":[{"value":"11 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Bijal Shah has received consultant and education fees from Amgen, Pfizer, Novartis, BMS\/Celgene\/Juno, Kite, a Gilead company, Precision Biosciences, Jazz, Beigene, Adaptive, Century Therapeutics, and Autolus; and clinical trial grants from Kite, a Gilead company, Jazz, and Servier. Jenny M.H. Chen, Julie E. Park, and Sam Keeping are employees of PRECISIONheor, funded by Kite, a Gilead Company for this study. James J. Wu is an employee of Kite, a Gilead Company; has received honoraria from the Patient-Centered Outcomes Research Institute (PCORI), both as a member of the Rare Disease Advisory Panel, and as a grants reviewer for the Improving Methods Program; has received travel\/meeting support from Kite, a Gilead Company, and Amgen; owns stock in Gilead Sciences, Amgen, Abbott, AbbVie, Pfizer, Roche, Curis, Avid Biosciences, Evofem, Lensar, VBI Vaccines, and Viracta Therapeutics. Chaoling Feng is an employee of Kite, a Gilead Company and owns stock in Gilead Sciences. Lang Zhou is an employee of Kite, a Gilead Company and owns stock in AbbVie and Gilead Sciences. Tsveta Hadjiivassileva is an employee of Kite, a Gilead Company and owns stock in Gilead Sciences. Sally W. Wade has received consulting fees from Kite, a Gilead Company, Abbvie, and Johnson & Johnson. Fabio R. Kerbauy declares no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Results presented in this article are based on a retrospective analysis of data from published studies, and therefore no institutional board review was required. Review boards at participating institutions approved the ZUMA-3, INO-VATE, and TOWER trials.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}